Exelixis (EXEL)
(Delayed Data from NSDQ)
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:04 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:04 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
by Zacks Equity Research
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.
Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 127.03% and 36.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Shattuck Labs (STTK) delivered earnings and revenue surprises of -2.44% and 82.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q2 results are likely to gain from growth in Emerging Markets and Europe and expansion of business activities in Japan, offset by declines in North America.
Can Amgen (AMGN) Keep the Beat Streak Alive in Q2 Earnings?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Exelixis (EXEL) Down 6.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
by Zacks Equity Research
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
Exelixis (EXEL) International Revenue Performance Explored
by Zacks Equity Research
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.
Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
What's in the Cards for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
by Zacks Equity Research
Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.